Optometrists in Winnemucca, NV Accepting Medicare
7 Optometrists found. Showing 1 - 7
 Bengoa Eye Care Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1050 Hanson St, Winnemucca, NV 89445 Phone: 775-625-3937 Fax: 775-625-3938 |
Northern Nevada Eyecare Ltd Optometrist Medicare: Not Enrolled in Medicare Practice Location: 50 E Haskell St Suite A, Winnemucca, NV 89445 Phone: 775-623-5211 Fax: 775-623-5236 |
Vision Consultants Optometrist Medicare: Not Enrolled in Medicare Practice Location: 118 E Haskell St, Winnemucca, NV 89445 Phone: 775-375-8869 |
Northern Nevada Eyecare Ltd Optometrist Medicare: Not Enrolled in Medicare Practice Location: 50 E Haskell St., Suite A, Winnemucca, NV 89445 Phone: 775-623-5211 Fax: 775-623-5236 |
 Amy E Sullivan, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1050 Hanson St, Winnemucca, NV 89445 Phone: 756-253-9377 Fax: 775-625-3938 |
Amy E Sullivan Llc Optometrist Medicare: Medicare Enrolled Practice Location: 1050 Hanson St, Winnemucca, NV 89445 Phone: 775-625-3937 Fax: 775-625-3938 |
B. Michael Southam, Od, Pc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 625 Sheehan St Apt E, Winnemucca, NV 89445 Phone: 775-625-4733 Fax: 775-625-4735 |
News Archive
Photovoice interventions could lead to complete recovery of sexual assault survivors
One out of every six American women has experienced a sexual assault or an attempted sexual assault or rape in her lifetime, according to the National Institute of Justice and the Centers for Disease Control and Prevention.
Impax' NDA for generic version of Adoxa receives final FDA approval
Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration has granted final approval of the Company's Abbreviated New Drug Application for its generic version of Adoxa.
New technology rapidly detects tumor response to chemotherapy
New technology developed by Duke University bioengineers can help clinicians more precisely detect whether specific cancer drugs are working, and should give basic researchers a powerful new tool to better understand the underlying mechanisms of cancer development.
Sarepta Therapeutics plans to submit eteplirsen NDA for treatment of Duchenne muscular dystrophy
Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today announced it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration by the end of 2014 for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD).
Zenobia, Lundbeck enter research collaboration for LRRK2 Parkinson's disease target
Zenobia Therapeutics, Inc. the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2. Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.
› Verified 5 days ago
Physical Therapists
Optometrists
Chiropractors
Occupational Therapists
Speech-Language Pathologists